Cell Therapeutics Posts $8.04 Million Feb. Net LossMonday 03/30/2009 6:06 PM ET - Dow Jones News
As of 12:00 AM ET 3/30/09
DOW JONES NEWSWIRES
Cell Therapeutics Inc. (CTIC) reported Monday a net loss attributable to common shareholders of $8.04 million for the month ended Feb. 28.
In a press release attached to a Securities and Exchange Commission filing, the Seattle company also said it will no longer record sales related to Zevalin as a result of the transfer of all assets exclusively related to RIT Oncology LLC to Spectrum Pharmaceuticals Inc. (SPPI). RIT Oncology had been a 50/50 joint venture between Cell Therapeutics and Spectrum.
Zevalin is a radioimmunotherapy drug that's used for some types of non-Hodgkin lymphoma.
-By Gee L. Lee, Dow Jones Newswires; 202-862-1346
Click here to go to Dow Jones NewsPlus, a web front page of today's most important business and market news, analysis and commentary:
http://www.djnewsplus.com/nae/al?rnd=arzBFYCmpOSRdm30qLi8mg%3D%3D. You can use this link on the day this article is published and the following day.